ESR1 and breast carcinoma: Distinct from the mechanism described above, TROJAN inhibits the interaction between the NF-κB pathway repressor NKRF and RELA, a transcriptional activator of the NF-κB pathway, thereby upregulating the expression of CDK2, which ultimately reverses the resistance of ER + breast cancer to a CDK4/6 inhibitor showing the anticancer activity (Jin et al., 2020).